Operator: Our next question comes from the line of David Nierengarten of Wedbush Securities.
David Nierengarten: I just had a couple kind of on the penetration of the markets. First, have there been centers, I know, thankfully, childhood cancers are rare occurrence. But have there been any centers that are repeated or have repeat dosing of patients? And then on your coverage of the academic centers, is there — do you have an estimate on how many patients utilize those centers as a percentage? Like is it 40%, 50%, 80%?
Rostislav Raykov: David, yes. So maybe I can answer the second one first. Yes, so if you look at the centers overall, it varies. So you have centers where the repeat customer orders, where they’re utilizing — most physicians are utilizing it. There are some centers where half of the physicians are utilizing it. So it varies. It’s sort of center-by-center, comfort-by-comfort from a physician-to-physician, disease-by-disease, of course, because our label plays into several tumor types and their experience and the growth that we’re seeing comes from really writing scripts, putting patients on drug and seeing the outstanding results, both from an efficacy perspective but importantly, safety perspective, only this product, I mean, here we are almost nine months into launch.
And there hasn’t been an A report which speaks to how good this drug is. As rarely would you see anything in pediatric oncology that — or any oncology product for that matter that has that. So that’s what makes us very, very excited because we have a really, really good treatment for these kids. Sorry, what was the first question, again?
David Nierengarten: I think the first question was actually on the repeat customers. The next one was the kind of the number of academic centers or — as the number of academic centers signed up and the percentage of patients typically that they treat in year out of the total population. So majority is 70%, yes.
Rostislav Raykov: Yes, it’s pretty — it’s — like I said, it’s pretty well distributed. Maybe, Robert, you have some more granularity on these numbers but it’s pretty well distributed between the academic centers and some of the smaller hospitals which typically in early launch tend to be some of the early adopters.
Robert Andrade: Yes. I’ll add, David, similar to what Rosty said. Every center is unique in the sense of the amount of patients, the type of patient it sees and their philosophy on how they roll out whether before formulary approval or after formulary approval. Similar to what we said already, we have gained some major academic centers recently. And so, we’re quite excited about that and anticipating some orders there. So hopefully, as the months go out, we actually learn more from all our centers in terms of patient numbers, PEDMARK applicability.
Operator: Thank you. This concludes our question-and-answer session. I would now like to turn the conference back to Rosty Raykov.
Rostislav Raykov: I would like to thank you all for joining us today. We look forward to updating you on our continued launch progress and corporate milestones in the future quarterly calls. Thank you and have a great morning.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
